Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktørH Offline
    Helge_LarsenPI-redaktør
    wrote on sidst redigeret af
    #1310

    God morgen. 🙂

    1 Reply Last reply
    0
    • K Offline
      K Offline
      KWC
      wrote on sidst redigeret af
      #1311

      Morgen. Og tak 🙂

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #1312

        thanks Helge; that means a difference with real Q1 figures of almost 10% now

        1 Reply Last reply
        0
        • BulderB Offline
          BulderB Offline
          Bulder
          wrote on sidst redigeret af
          #1313

          Tak Helge

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bibob
            wrote on sidst redigeret af
            #1314

            God morgen fra solrige Torremolinos. :-). Og tak for tallene Helge. De ser solide ud. Måske derfor det pæne luk i går. 😉

            1 Reply Last reply
            0
            • M Offline
              M Offline
              Mcjean
              wrote on sidst redigeret af
              #1315

              Tak for input JDam!

              1 Reply Last reply
              0
              • M Offline
                M Offline
                Mcjean
                wrote on sidst redigeret af
                #1316

                Nu sagde JDW jo også (engang i feb. tror jeg) at det så ud som om de havde løst flaskehalsproblematikken i US, hvolket jo burde udløse nogle andre salgstal.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1317

                  Tisotumab Vedotin mention in the Seattle Genetics Q1 2018 Results http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2345077

                  1 Reply Last reply
                  0
                  • Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktørH Offline
                    Helge_LarsenPI-redaktør
                    wrote on sidst redigeret af
                    #1318

                    " Tisotumab Vedotin (TV) Program Activities

                    Planned Pivotal Trial Initiation: Seattle Genetics and Genmab plan to advance TV into a pivotal phase 2 trial for recurrent or metastatic cervical cancer that relapses or progresses after standard of care treatment for cervical cancer. The single-arm trial is designed to enroll approximately 100 women and could potentially support registration under the FDA’s accelerated approval regulations.

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #1319

                      The trial is expected to begin in the first half of 2018".

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #1320

                        "Expanding Clinical Development Program: Seattle Genetics and Genmab plan to initiate in 2018 a phase 2 trial of TV as part of a combination regimen in women with first-line metastatic cervical cancer. In addition, a phase 2 trial is expected to begin in 2018 to evaluate TV monotherapy in a range of other solid tumors"
                        .

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #1321

                          Thanks E L

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #1322

                            also the Earnings Call Transcript for those interested - https://seekingalpha.com/article/4166737-seattle-genetics-sgen-q1-2018-results-earnings-call-transcript?part=single - doesnt say much more, except that they work closely with Genmab, have visited them and that they think they will accrue the trials very rapidly and then get data 'very fast'.

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #1323

                              Tak E L, Helge, JDam og god formiddag.

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bibob
                                wrote on sidst redigeret af
                                #1324

                                Også tak herfra til alle for gode links og kommentarer med indhold og indsigt. :-). Ingen nævnt og ingen glemt. 🙂

                                1 Reply Last reply
                                0
                                • BulderB Offline
                                  BulderB Offline
                                  Bulder
                                  wrote on sidst redigeret af
                                  #1325

                                  Der forskes en del i målrettet actinium 225 terapi - ikke mindst i prostata cancer. https://www.sciencedaily.com/releases/2017/10/171003111051.htm Men også i MM kører der kliniske forsøg. F.eks. Lintuzumab (cd33) koblet med Ac225. https://www.clinicaltrials.gov/ct2/show/NCT02998047?term=actinium&rank=2

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #1326

                                    Problemet med dara og Ac225 kan være, at cd38 er udtrykt mange steder i kroppen, og at bivirkninger derfor vil være tunge. Derfor vil den stærke effekt af koblingen, som de prækliniske studier antyder, nok mest være eftertragtet af sen stadie patienter.

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #1327

                                      Og måske er cd38 et uegnet target, når det kommer til den kliniske afprøvning.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #1328

                                        Article in the Neurology magazine on the MIRROR study (Ofa/MS) http://n.neurology.org/content/early/2018/04/25/WNL.0000000000005516

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          pauly
                                          wrote on sidst redigeret af
                                          #1329

                                          Thankyou. So is that good or not so good compared to others?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger